Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Year: 2020
Type: article
Abstract: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal tandem duplication mutated AML, allogeneic hematopoietic stem-cell transplantation (SCT) was commonly performed in first complete remission. Remarkable progress has been made in frontline treatments with the incorporation of FLT3 inhibitors and the development of highly sensitive minimal/measurable residual disease assays. Similarly, recent progress in allogeneic hematopoietic SCT includes improvement of transplant techniques, the use of haploidentical donors in patients lacking an HLA matched donor, and the introduction of FLT3 inhibitors as post-transplant maintenance therapy. Nevertheless, current transplant strategies vary between centers and differ in terms of transplant indications based on the internal tandem duplication allelic ratio and concomitant nucleophos-min-1 mutation, as well as in terms of post-transplant maintenance/consolidation. This review generated by international leukemia or transplant experts, mostly from the European Society for Blood and Marrow Transplantation, attempts to develop a position statement on best approaches for allogeneic hematopoietic SCT for AML with FLT3-internal tandem duplication including indications for and modalities of such transplants and on the potential optimization of post-transplant maintenance with FLT inhibitors.
Source: Haematologica
Authors: Ali Bazarbachi, Gesine Bug, Frederic Baron, Eolia Brissot, Fabio Ciceri, Iman Abou Dalle, Hartmut Döhner, Jordi Esteve, Yngvar Floisand, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Elias Jabbour, Mahmoud Aljurf, Hagop Kantarjian, Mohamed Kharfan-Dabaja, Myriam Labopin, Francesco Lanza, Florent Malard, Zinaida Peric, Thomas Prebet, Farhad Ravandi, Annalisa Ruggeri, Jaime Sanz, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Norbert Vey, Bipin N Savani, Arnon Nagler, Mohamad Mohty
Institutions: American University of Beirut Medical Center, American University of Beirut, Goethe University Frankfurt, University Hospital Frankfurt, Centre Hospitalier Universitaire de Liège, Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, University Hospital Ulm, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Oslo University Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Leeds Teaching Hospitals NHS Trust, European Society for Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, King Faisal Specialist Hospital & Research Centre, Mayo Clinic, Mayo Clinic in Florida, University Hospital Centre Zagreb, University of Zagreb, Yale University, Bambino Gesù Children's Hospital, Hôpital Saint-Louis, Istituti di Ricovero e Cura a Carattere Scientifico, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria La Fe, University Hospital Augsburg, Memorial Sloan Kettering Cancer Center, University of Patras, Erasmus MC, Institut Paoli-Calmettes, Vanderbilt University Medical Center, Tel Aviv University, Sheba Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W3014928753